Measuring the effectiveness and impact of an open innovation platform

Drug Discovery Today

Volumn 22, Issue 5, 2017, Pages 776-785

  Carroll, Glenn P ^a   Srivastava, Sanjay ^a   Volini, Adam S ^a   Piñeiro Núñez, Marta M ^b   Vetman, Tatiana ^b  

^a Deloitte   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DECISION MAKING; DRUG DEVELOPMENT; DRUG INDUSTRY; FUTUROLOGY; HEALTH; HUMAN; INDUSTRY AND INDUSTRIAL PHENOMENA; INVESTMENT; OPEN INNOVATION; PATENT; QUALITATIVE RESEARCH; QUANTITATIVE STUDY; REVIEW; INVENTION; MASS COMMUNICATION; THEORETICAL MODEL;

DIFFUSION OF INNOVATION; DRUG DISCOVERY; DRUG INDUSTRY; INVENTIONS; MODELS, THEORETICAL;

EID: 85011854041     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2017.01.009     Document Type: Review

References (33)

1. 1 Chesbrough, H.W., Open Innovation: The New Imperative for Creating and Profiting from Technology. 2003, Harvard Business School Press, Boston.
2. 2 Chesbrough, H.W., Vanhaverbeke, W., West, J., New Frontiers in Open Innovation. 2014, Oxford University Press.
3. 3 Hunter, J., Stephens, S., Is open innovation the way forward for big pharma?. Nat. Rev. Drug Discov. 9 (2010), 87–88.
4. 4 Bianchi, M., et al. Organisational modes for Open Innovation in the bio-pharmaceutical industry: an exploratory analysis. Technovation 31 (2011), 22–33.
5. 5 Bennani, Y.L., Drug discovery in the next decade: innovation needed ASAP. Drug Discov. Today 16 (2011), 779–792.
6. 6 Khanna, I., Drug discovery in pharmaceutical industry: productivity challenges and trends. Drug Discov. Today 17 (2012), 1088–1102.
7. 7 Schuhmacher, A., et al. Models for open innovation in the pharmaceutical industry. Drug Discov. Today 18 (2013), 1133–1137.
8. 8 Hunter, J., Collaboration for innovation is the new mantra for the pharmaceutical industry. Spring 14. Drug Discov. World, 2014 (http://www.ddw-online.com).
9. 9 Ehrismann, D., Patel, D.D., University-industry collaborations: models, drivers and cultures. Swiss Med. Wkly., 2015, 10.4414/smw.2015.14086 (http://www.smw.ch/content/smw-2015-14086/).
10. 10 Bentzien, J., et al. Crowdsourcing in pharma: a strategic framework. Drug Discov. Today, 2015, 10.1016/j.drudis.2015.01.011.
11. 11 Reichman, M., Simpson, P.B., Open innovation in early drug discovery: roadmaps and roadblocks. Drug Discov. Today, 2015, 10.1016/j.drudis.2015.12.008.
12. 12 Holmes, D., A new chapter in innovation. Nature 533 (2016), S54–S55.
13. 13 Executing an Open Innovation Model: Cooperation is Key to Competition for Biopharmaceutical Companies; Deloitte website, Accessed 6 September 2016, http://www2.deloitte.com/content/dam/Deloitte/us/Documents/life-sciences-health-care/us-lshc-open-innovation.pdf.
14. 14 Kola, I., Landis, J., Can the pharmaceutical industry reduce attrition rates?. Nat. Rev. Drug Discov. 3 (2004), 711–716.
15. 15 Scannell, J.W., et al. Diagnosing the decline in pharmaceutical R&D efficiency. Nat. Rev. Drug Discov. 11 (2012), 191–200.
16. 16 DiMasi, J.A., et al. Innovation in the pharmaceutical industry: new estimates of R&D costs. J. Health Economics 47 (2016), 20–33.
17. 17 Hughes, J.P., et al. Principles of early drug discovery. Br. J. Pharmacol., 2010, 10.1111/j.1476-5381.2010.01127.x (http://onlinelibrary.wiley.com).
18. 18 Research & Development in the Pharmaceutical Industry, OIDD website, Accessed September, 2016. https://openinnovation.lilly.com/dd/includes/pdf/R_and_D_White_Paper_Final.pdf.
19. 19 Michelino, F., et al. Measuring open innovation in the bio-pharmaceutical industry. Creativity Innovation Manage., 2015, 10.1111/caim.12072 (http://onlinelibrary.wiley.com).
20. 20 Erkens, M., et al. Measuring open innovation: a toolkit for successful innovation teams. Performance 6 (2014), 12–23.
21. 21 OIDD website, What is OIDD? https://openinnovation.lilly.com/dd/what-is-oidd/ Accessed September, 2016.
22. 22 Schwartz, K., Huff, B., The story of Eli Lilly's open innovation journey: how one company developed a mature model. PDMA Visions 34 (2010), 19–22.
23. 23 Lyles, M., Lai, Y., Dhanaraj, C., Innovation Without Walls: Alliance Management at Eli Lilly and Company. 2007, Harvard Business Review.
24. 24 Owens, P.K., et al. A decade of innovation in pharmaceutical R&D: the chorus model. Nat. Rev. Drug Discov. 14 (2015), 17–28.
25. 2 assay panel. J. Biomol. Screen. 16:6 (2011), 588–602.
26. 26 OIDD Website, Program Agreements, https://openinnovation.lilly.com/dd/getting-started/program-agreements.html.
27. 27 McGilvray, A., Compound screening: fresh hunting ground. Nature 533 (2016), S65–S67.
28. 28 OIDD website, What We Offer, https://openinnovation.lilly.com/dd/what-we-offer/ Accessed September 2016.
29. 29 Alvim-Gaston, M., et al. Open innovation drug discovery (OIDD): a potential path to novel therapeutic chemical space. Curr. Topics Med. Chem. 14 (2014), 294–303.
30. 30 OIDD Website, Protecting Your Intellectual Property, https://openinnovation.lilly.com/dd/what-is-oidd/protecting-your-intellectual-property.html.
31. 31 Within Lilly, the term “confirmed active” excludes so-called PAIN compounds that interfere with assays or have promiscuous activity, thus over-inflating success rate. For an excellent description of PAINs, see Baell J., Walters M.A. (2014) Chemistry: Chemical Con Artists Foil Drug Discovery. Nature 513(7519):481–3. DOI: 10.1038/513481a.
32. 32 OIDD Website, Compound Acquisition, https://openinnovation.lilly.com/dd/what-we-offer/compound-acquisition.html.
33. 33 OIDD Website, OIDD Screening, https://openinnovation.lilly.com/dd/what-we-offer/screening.html.